FluoroPharma Medical, Inc. (FPMI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FluoroPharma Medical, Inc. (FPMI) with AI Score 51/100 (Hold). FluoroPharma Medical, Inc. is a biopharmaceutical company focused on developing molecular imaging pharmaceuticals for cardiology. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026FluoroPharma Medical, Inc. (FPMI) Healthcare & Pipeline Overview
FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of molecular imaging pharmaceuticals, primarily targeting cardiology applications such as coronary artery disease (CAD) diagnosis. Their pipeline includes BFPET and CardioPET, imaging agents designed to improve CAD assessment and management, positioning them within the niche molecular imaging market.
Investment Thesis
FluoroPharma Medical, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its molecular imaging agents, BFPET and CardioPET, targeting the diagnosis of coronary artery disease (CAD). Positive Phase IIa trial results for CardioPET could serve as a significant catalyst, potentially attracting strategic partnerships or acquisition interest. However, the company's limited financial resources, small team, and reliance on clinical trial outcomes introduce substantial risks. The negative beta of -69.72 suggests an inverse correlation with the market, which may be misleading given the company's stage and specific risks. Investors should carefully weigh the potential upside against the inherent uncertainties of biopharmaceutical development and the company's OTC market listing.
Based on FMP financials and quantitative analysis
Key Highlights
- FluoroPharma Medical, Inc. focuses on molecular imaging pharmaceuticals for cardiology, specifically coronary artery disease (CAD).
- BFPET, a key product candidate, has completed Phase I clinical trials for stress-testing in CAD patients.
- CardioPET, another product candidate, is in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients.
- The company has license agreements with Massachusetts General Hospital and Sinotau USA.
- FluoroPharma Medical, Inc. has a market capitalization of $0.00B, indicating its small size and early stage of development.
Competitors & Peers
Strengths
- Proprietary molecular imaging technology
- Focus on a specific therapeutic area (cardiology)
- Clinical data supporting the efficacy of their products
- Experienced management team
Weaknesses
- Limited financial resources
- Small team
- Reliance on clinical trial outcomes
- OTC market listing
Catalysts
- Upcoming: CardioPET Phase IIa trial results expected in late 2026, which could validate the technology and attract partnerships.
- Ongoing: Continued clinical development of BFPET for stress-testing in CAD patients.
- Ongoing: Potential for strategic partnerships with larger pharmaceutical or medical device companies.
- Upcoming: Possible expansion into new cardiovascular applications within the next 3-5 years.
- Ongoing: Exploration of geographic expansion into international markets.
Risks
- Potential: Clinical trial failures for BFPET or CardioPET could significantly impact the company's value.
- Ongoing: Limited financial resources and small team pose challenges to product development and commercialization.
- Ongoing: Competition from established players in the medical imaging market.
- Potential: Regulatory hurdles and delays in obtaining FDA approval.
- Ongoing: OTC market listing increases the risk of price volatility and manipulation.
Growth Opportunities
- Successful Completion of CardioPET Phase IIa Trial: Positive results from the ongoing Phase IIa clinical trial for CardioPET could significantly enhance its market value. This trial assesses myocardial blood flow and metabolism in CAD patients. Success would validate the technology and attract potential partnerships or funding for further development and larger Phase III trials, potentially leading to commercialization within 3-5 years. The market for advanced cardiac imaging is projected to reach billions of dollars, offering substantial revenue potential.
- Strategic Partnerships for BFPET Commercialization: FluoroPharma could pursue strategic partnerships with larger pharmaceutical or medical device companies to commercialize BFPET, which has completed Phase I trials. Partnering would provide access to resources and expertise for regulatory approval and market launch. The market for stress-testing agents is substantial, and a successful partnership could generate significant revenue streams within 2-3 years.
- Expansion into New Cardiovascular Applications: FluoroPharma can leverage its molecular imaging technology to expand into new cardiovascular applications beyond CAD diagnosis. This could include imaging agents for heart failure, stroke, or peripheral artery disease. Expanding the product pipeline would diversify revenue streams and reduce reliance on single product success. This expansion could begin within the next 3-5 years, requiring further research and development.
- Geographic Expansion into International Markets: FluoroPharma could explore opportunities to expand its market reach into international markets, particularly Europe and Asia, where there is a growing demand for advanced cardiac imaging technologies. This expansion would require regulatory approvals and strategic partnerships with local distributors. International expansion could begin within 3-5 years, contingent on successful clinical trials and regulatory pathways.
- Development of Companion Diagnostics: FluoroPharma can develop companion diagnostics to identify patients who are most likely to benefit from specific cardiovascular therapies. This would enhance the value proposition of its imaging agents and create opportunities for personalized medicine. Companion diagnostics could improve treatment outcomes and reduce healthcare costs. Development could begin within 2-3 years, requiring collaboration with pharmaceutical companies.
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cardiovascular applications
- Geographic expansion into international markets
- Development of companion diagnostics
Threats
- Competition from established players in medical imaging
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitive Advantages
- Proprietary molecular imaging technology
- Patent protection for key product candidates
- Clinical data supporting the efficacy of their products
- Established relationships with key opinion leaders in cardiology
About FPMI
Founded in 2003 and headquartered in Montclair, New Jersey, FluoroPharma Medical, Inc. is a biopharmaceutical company focused on the development of molecular imaging pharmaceuticals, with a particular emphasis on cardiology. The company's mission is to improve the diagnosis and management of cardiovascular diseases through advanced imaging technologies. Its lead product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial for stress-testing in patients with suspected or proven coronary artery disease (CAD), and CardioPET, a molecular imaging agent currently in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients. FluoroPharma operates through license agreements with institutions like Massachusetts General Hospital and Sinotau USA, and has established clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. The company's focus on molecular imaging in cardiology aims to provide clinicians with enhanced diagnostic tools for better patient outcomes. Despite its small size, with only 4 employees, FluoroPharma is actively pursuing clinical development and partnerships to advance its pipeline.
What They Do
- Develop molecular imaging pharmaceuticals.
- Focus on cardiology applications.
- Create imaging agents for coronary artery disease (CAD) diagnosis.
- Conduct clinical trials to assess the safety and efficacy of their products.
- Seek regulatory approval for their products from the FDA.
- Commercialize their products through partnerships or direct sales.
Business Model
- Develop and patent novel molecular imaging agents.
- Conduct clinical trials to demonstrate safety and efficacy.
- License or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through licensing fees, milestone payments, and royalties.
Industry Context
FluoroPharma Medical, Inc. operates within the biotechnology industry, specifically targeting the molecular imaging segment within cardiology. The market for cardiovascular imaging is growing, driven by the increasing prevalence of heart disease and the demand for more accurate diagnostic tools. Competition includes established players in medical imaging and other biotechnology companies developing novel diagnostic agents. FluoroPharma's success depends on its ability to differentiate its products through superior efficacy, safety, and cost-effectiveness. The company's focus on CAD diagnosis positions it within a critical area of unmet medical need.
Key Customers
- Cardiologists
- Hospitals and imaging centers
- Patients with suspected or proven coronary artery disease (CAD)
Financials
Chart & Info
FluoroPharma Medical, Inc. (FPMI) stock price: Price data unavailable
Latest News
No recent news available for FPMI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FPMI.
Price Targets
Wall Street price target analysis for FPMI.
MoonshotScore
What does this score mean?
The MoonshotScore rates FPMI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Edward L. Lyons Jr.
Unknown
Information on Edward L. Lyons Jr.'s background is not available in the provided data. Without further information, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Information on Edward L. Lyons Jr.'s track record is not available in the provided data. Without further information, it is impossible to provide details on key achievements, strategic decisions, or company milestones under his leadership.
FPMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that FluoroPharma Medical, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is generally reserved for companies with distressed financials, early-stage ventures, or those that choose not to comply with stricter reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's legal registration and compliance status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and potential dilution.
- Monitor trading activity and price volatility.
- Consult with a qualified financial advisor.
- Existence of a physical headquarters and contact information
- Presence of a management team and board of directors
- Patents or intellectual property related to their technology
- Agreements with reputable institutions like Massachusetts General Hospital
- Completion of Phase I and Phase IIa clinical trials
Common Questions About FPMI
What does FluoroPharma Medical, Inc. do?
FluoroPharma Medical, Inc. is a biopharmaceutical company focused on developing and commercializing molecular imaging pharmaceuticals for cardiology, particularly for the diagnosis and management of coronary artery disease (CAD). Their lead product candidates, BFPET and CardioPET, are designed to improve the accuracy and efficiency of cardiac imaging, providing clinicians with better tools for assessing myocardial blood flow and metabolism. The company aims to address the unmet needs in cardiovascular diagnostics through innovative imaging technologies.
What do analysts say about FPMI stock?
As of March 18, 2026, there is no readily available analyst coverage for FluoroPharma Medical, Inc. This lack of coverage is typical for companies trading on the OTC market with a small market capitalization. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in thinly traded, early-stage biopharmaceutical companies. Key valuation metrics are not widely available, and growth considerations are primarily tied to the successful development and commercialization of their product pipeline.
What are the main risks for FPMI?
FluoroPharma Medical, Inc. faces several significant risks inherent to its business and market position. As a biopharmaceutical company, clinical trial failures for BFPET or CardioPET represent a major risk, potentially halting product development and eroding investor confidence. The company's limited financial resources and small team pose challenges to advancing its pipeline and competing with larger, more established players. Additionally, the OTC market listing increases the risk of price volatility and manipulation, making it crucial for investors to exercise caution.
What are the key factors to evaluate for FPMI?
FluoroPharma Medical, Inc. (FPMI) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary molecular imaging technology. Primary risk to monitor: Potential: Clinical trial failures for BFPET or CardioPET could significantly impact the company's value.. This is not financial advice.
How frequently does FPMI data refresh on this page?
FPMI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FPMI's recent stock price performance?
Recent price movement in FluoroPharma Medical, Inc. (FPMI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary molecular imaging technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FPMI overvalued or undervalued right now?
Determining whether FluoroPharma Medical, Inc. (FPMI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FPMI?
Before investing in FluoroPharma Medical, Inc. (FPMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and limited analyst coverage.
- Financial data is based on available information and may not be comprehensive.
- The AI analysis is pending and may provide additional insights in the future.